Potential prognostic and predictive value of UBE2N, IMPDH1, DYNC1LI1 and HRASLS2 in colorectal cancer stool specimens.

IF 2.3 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Yu-Nung Chen, Cheng-Yen Shih, Shu-Lin Guo, Chih-Yi Liu, Ming-Hung Shen, Shih-Chang Chang, Wei-Chi Ku, Chi-Cheng Huang, Chi-Jung Huang
{"title":"Potential prognostic and predictive value of UBE2N, IMPDH1, DYNC1LI1 and HRASLS2 in colorectal cancer stool specimens.","authors":"Yu-Nung Chen,&nbsp;Cheng-Yen Shih,&nbsp;Shu-Lin Guo,&nbsp;Chih-Yi Liu,&nbsp;Ming-Hung Shen,&nbsp;Shih-Chang Chang,&nbsp;Wei-Chi Ku,&nbsp;Chi-Cheng Huang,&nbsp;Chi-Jung Huang","doi":"10.3892/br.2023.1604","DOIUrl":null,"url":null,"abstract":"<p><p>Colorectal cancer (CRC) is the most common gastrointestinal malignancy worldwide. The poor specificity and sensitivity of the fecal occult blood test has prompted the development of CRC-related genetic markers for CRC screening and treatment. Gene expression profiles in stool specimens are effective, sensitive and clinically applicable. Herein, a novel advantage of using cells shed from the colon is presented for cost-effective CRC screening. Molecular panels were generated through a series of leave-one-out cross-validation and discriminant analyses. A logistic regression model following reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and immunohistochemistry was used to validate a specific panel for CRC prediction. The panel, consisting of ubiquitin-conjugating enzyme E2 N (UBE2N), inosine monophosphate dehydrogenase 1 (IMPDH1), dynein cytoplasmic 1 light intermediate chain 1 (DYNC1LI1) and phospholipase A and acyltransferase 2 (HRASLS2), accurately recognized patients with CRC and could thus be further investigated as a potential prognostic and predictive biomarker for CRC. UBE2N, IMPDH1 and DYNC1LI1 expression levels were upregulated and HRASLS2 expression was downregulated in CRC tissues. The predictive power of the panel was 96.6% [95% confidence interval (CI), 88.1-99.6%] sensitivity and 89.7% (95% CI, 72.6-97.8%) specificity at a predicted cut-off value at 0.540, suggesting that this four-gene panel testing of stool specimens can faithfully mirror the state of the colon. On the whole, the present study demonstrates that screening for CRC or cancer detection in stool specimens collected non-invasively does not require the inclusion of an excessive number of genes, and colonic defects can be identified via the detection of an aberrant protein in the mucosa or submucosa.</p>","PeriodicalId":8863,"journal":{"name":"Biomedical reports","volume":"18 3","pages":"22"},"PeriodicalIF":2.3000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8f/a2/br-18-03-01604.PMC9945078.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3892/br.2023.1604","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Colorectal cancer (CRC) is the most common gastrointestinal malignancy worldwide. The poor specificity and sensitivity of the fecal occult blood test has prompted the development of CRC-related genetic markers for CRC screening and treatment. Gene expression profiles in stool specimens are effective, sensitive and clinically applicable. Herein, a novel advantage of using cells shed from the colon is presented for cost-effective CRC screening. Molecular panels were generated through a series of leave-one-out cross-validation and discriminant analyses. A logistic regression model following reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and immunohistochemistry was used to validate a specific panel for CRC prediction. The panel, consisting of ubiquitin-conjugating enzyme E2 N (UBE2N), inosine monophosphate dehydrogenase 1 (IMPDH1), dynein cytoplasmic 1 light intermediate chain 1 (DYNC1LI1) and phospholipase A and acyltransferase 2 (HRASLS2), accurately recognized patients with CRC and could thus be further investigated as a potential prognostic and predictive biomarker for CRC. UBE2N, IMPDH1 and DYNC1LI1 expression levels were upregulated and HRASLS2 expression was downregulated in CRC tissues. The predictive power of the panel was 96.6% [95% confidence interval (CI), 88.1-99.6%] sensitivity and 89.7% (95% CI, 72.6-97.8%) specificity at a predicted cut-off value at 0.540, suggesting that this four-gene panel testing of stool specimens can faithfully mirror the state of the colon. On the whole, the present study demonstrates that screening for CRC or cancer detection in stool specimens collected non-invasively does not require the inclusion of an excessive number of genes, and colonic defects can be identified via the detection of an aberrant protein in the mucosa or submucosa.

Abstract Image

Abstract Image

Abstract Image

UBE2N、IMPDH1、DYNC1LI1和HRASLS2在结直肠癌粪便标本中的潜在预后和预测价值。
结直肠癌(CRC)是世界上最常见的胃肠道恶性肿瘤。粪便潜血检查的特异性和敏感性较差,促使CRC相关遗传标记的发展用于CRC筛查和治疗。粪便标本的基因表达谱是有效、敏感和临床应用的。在此,使用结肠脱落细胞的新优势被提出用于具有成本效益的CRC筛查。通过一系列留一交叉验证和判别分析生成分子面板。采用逆转录-定量聚合酶链反应(RT-qPCR)和免疫组织化学的逻辑回归模型来验证CRC预测的特异性面板。该小组由泛素偶联酶E2N (UBE2N)、肌苷单磷酸脱氢酶1 (IMPDH1)、动力蛋白细胞质1轻中间链1 (DYNC1LI1)和磷脂酶A和酰基转移酶2 (HRASLS2)组成,可以准确识别CRC患者,因此可以进一步研究作为CRC的潜在预后和预测性生物标志物。在结直肠癌组织中,UBE2N、IMPDH1和DYNC1LI1表达水平上调,HRASLS2表达下调。该小组的预测能力为96.6%[95%置信区间(CI), 88.1-99.6%]的敏感性和89.7% (95% CI, 72.6-97.8%)的特异性,预测临界值为0.540,表明这种粪便标本的四基因小组检测可以忠实地反映结肠的状态。总体而言,本研究表明,在非侵入性收集的粪便标本中筛查结直肠癌或癌症检测不需要包含过多的基因,结肠缺陷可以通过检测粘膜或粘膜下层的异常蛋白来识别。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Biomedical reports
Biomedical reports MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
4.10
自引率
0.00%
发文量
86
期刊介绍: Biomedical Reports is a monthly, peer-reviewed journal, dedicated to publishing research across all fields of biology and medicine, including pharmacology, pathology, gene therapy, genetics, microbiology, neurosciences, infectious diseases, molecular cardiology and molecular surgery. The journal provides a home for original research, case reports and review articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信